Answer
In MagnetisMM-3, diarrhoea was very common in the 183 patients receiving Elrexfio (elranatamab) at the recommended dosing regimen, occurring in 42.1% overall, with Grade 3 or 4 diarrhoea in 2.7%.
Sources for this answer
- ELREXFIO 40 mg/mL solution for injectionPfizer Limited · emc · SmPC §4.8 Undesirable effects · Version 10Document updated
Sources checked